This content is not available in your region

GSK grabs new drug development head from Boehringer

Access to the comments Comments
Text size Aa Aa

LONDON (Reuters) – GlaxoSmithKline <GSK.L> has hired Chris Corsico from German drugmaker Boehringer Ingelheim to fill the new role of senior vice-president development as the company reshapes its research strategy, a spokesman for the British group said on Tuesday.

Corsico, currently chief medical officer at Boehringer, will start at GSK on January 1, reporting to research head Hal Barron.

Barron himself joined GSK at the start of 2018 in a key appointment for new Chief Executive Emma Walmsley, whose top priority is to improve research productivity in pharmaceuticals.

(Reporting by Ben Hirschler; Editing by Adrian Croft)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.